Award of NHS National Framework for Transition Products (Dimethyl Fumarate, Teriflunomide, Trabectedin, Apixaban, Sapropterin) to Multiple Suppliers

About

NHS England awarded a contract to Teva UK Limited, Kent Pharma Ltd, Celix Pharma Ltd., Dr.Reddy's Laboratories (UK) Limited, Thornton and Ross Ltd, Glenmark Pharmaceuticals Europe Limited, Mylan, Selective Supplies Ltd., Sandoz Ltd, and LogixX Pha for the NHS National Framework for Transition products commencing 1 May 2024.

The framework covers the supply of dimethyl fumarate, teriflunomide, and trabectedin under Lot 1 (NWLN: 01/05/2024 to 31/01/2025, 9 months), Lot 2 (CESW: 01/05/2024 to 30/09/2025, 17 months), and Lot 3 (LSNE: 01/05/2024 to 30/09/2025, 17 months), as well as apixaban and sapropterin under Lot 1 (DNW+DNE+DCE: 01/05/2024 to 30/09/2025, 17 months) and Lot 2 (DLS+DLN+DSW: 01/05/2024 to 30/09/2025, 17 months).

The framework agreement includes an option to extend up to a maximum of 24 months at the discretion of the Authority.

The contract value is £7,559,000.